Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy
Year: 2014
Type: article
Study design: Observational Study
Abstract: There is ample evidence that neoadjuvant chemotherapy of breast carcinoma is particularly efficient if the tumor presents signs of either a pre-existent or therapy-induced anticancer immune response. Antineoplastic chemotherapies are particularly beneficial if they succeed in inducing immunogenic cell death, hence converting the tumor into its own therapeutic vaccine. Immunogenic cell death is characterized by a pre-mortem stress response including endoplasmic reticulum stress and autophagy. Based on these premises, we attempted to identify metagenes that reflect an intratumoral immune response or local stress responses in the transcriptomes of breast cancer patients. No consistent correlations between immune- and stress-related metagenes could be identified across several cohorts of patients, representing a total of 1045 mammary carcinomas. Moreover, few if any, of the stress-relevant metagenes influenced the probability of pathological complete response to chemotherapy. In contrast, several immune-relevant metagenes had a significant positive impact on response rates. This applies in particular to a CXCL13-centered, highly reproducible metagene signature reflecting the intratumoral presence of interferon-γ-producing T cells.
Source: OncoImmunology
DOI: 10.4161/onci.27884
Institutions: Inserm, Sorbonne Paris Cité, Centre de Recherche des Cordeliers, La Ligue Contre le Cancer, Université Paris Descartes, Institut Gustave Roussy, Laboratoire d’immunologie intégrative du cancer, Université Pierre-et-Marie-Curie, Université Paris-Sud, Délégation Paris 5, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,913
Funders: Cancer Research Institute, Association pour la Recherche sur le Cancer, European Commission, Agence Nationale de la Recherche, Fondation pour la Recherche Médicale, Ligue Contre le Cancer, Fondation de France, Institut National Du Cancer, Fondation Bettencourt Schueller, Labex Immuno-Oncology
OpenAlex ID: W2069350359
